Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 5/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PAM | P19021 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL813905 | 1.00 | DGKA (0.58) | DGKATSHRADRA2AADRA1AALDH1A1 | |
| SCHEMBL1033327 | 0.95 | DGKA (0.64) | DGKATSHRADRA2AADRA1AALDH1A1 | |
| SCHEMBL130621 | 0.93 | DGKA (0.52) | DGKATSHRADRA2AADRA1AALDH1A1 | |
| SCHEMBL28922182 | 0.93 | DGKA (0.68) | DGKATSHRADRA2AADRA1AALDH1A1 | |
| SCHEMBL813481 | 0.91 | DGKA (0.55) | DGKATSHRALDH1A1MAPTDNM1 | |
| SCHEMBL28126898 | 0.91 | TSHR (0.59) | DGKATSHRADRA2AADRA1AALDH1A1 | |
| SCHEMBL15131901 | 0.91 | DGKA (0.50) | DGKATSHRADRA2AADRA1AALDH1A1 | |
| SCHEMBL12200847 | 0.91 | DGKA (0.59) | DGKATSHRADRA2AADRA1AALDH1A1 | |
| SCHEMBL813361 | 0.90 | ADRA2A (0.54) | DGKATSHRADRA2AADRA1AALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL27753059 | 0.89 | TSHR (0.57) | DGKATSHRADRA2AADRA1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962784-B2 | Isocyanate terminated macromer and formulation thereof for use as an internal adhesive or sealant | ETHICON, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8470954-B2 | Diisocyanate terminated macromer and formulation thereof for use as an internal adhesive or sealant | ETHICON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8324292-B2 | Medically acceptable formulation of a diisocyanate terminated macromer for use as an internal adhesive or sealant | ETHICON, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8071663-B2 | Medically acceptable formulation of a diisocyanate terminated macromer for use as an internal adhesive or sealant | ETHICON, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-7968668-B2 | Diisocyanate terminated macromer and formulation thereof for use as an internal adhesive or sealant | ETHICON INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100158849-A1 | ISOCYANATE TERMINATED MACROMER AND FORMULATION THEREOF FOR USE AS AN INTERNAL ADHESIVE OR SEALANT | ETHICON, INC. | 2010-06-24 | — | — | US | disclosed |
| US-7728097-B2 | Method of making a diisocyanate terminated macromer | ETHICON, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20090222038-A1 | MEDICALLY ACCEPTABLE FORMULATION OF A DIISOCYANATE TERMINATED MACROMER FOR USE AS AN INTERNAL ADHESIVE OR SEALANT | ETHICON, INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221731-A1 | MEDICALLY ACCEPTABLE FORMULATION OF A DIISOCYANATE TERMINATED MACROMER FOR USE AS AN INTERNAL ADHESIVE OR SEALANT | ETHICON, INC. | 2009-09-03 | — | — | US | disclosed |
| US-20070276121-A1 | DIISOCYANATE TERMINATED MACROMER AND FORMULATION THEREOF FOR USE AS AN INTERNAL ADHESIVE OR SEALANT | ETHICON, INC. | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158849-A1 | ISOCYANATE TERMINATED MACROMER AND FORMULATION THEREOF FOR USE AS AN INTERNAL ADHESIVE OR SEALANT | ICAM1, ILK, MACF1 | DGKA 3393/4885TSHR 4859/4885ADRA2A 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.